trial

Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia

NCTId NCT00637234
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 54 (actual)
Sponsored by University of Cologne
Primary completion 2008-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
54 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2004-07
Primary completion
2008-04
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Oxcarbazepine

Sponsors

University of CologneLead Sponsor

Investigators

1
F. Markus Leweke, MDStudy Director

Sites

2 total
Taufkirchen (Vils), GermanyCologne, Germany

Linked catalysts

1
Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia — primary completion2008-04

Facts & assertions

4 sourced
Enrollment
54
Phase
PHASE2,PHASE3
Primary Completion Date
2008-04
Status
COMPLETED
relationships
The graph out of here
drug
Oxcarbazepine
drug
lead_sponsor
University of Cologne
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
F. Markus Leweke, MD
person